{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:11:31Z","timestamp":1790655091091,"version":"4.1.0"},"reference-count":58,"publisher":"The Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,10,1]]},"DOI":"10.1210\/en.2016-1358","type":"journal-article","created":{"date-parts":[[2016,8,15]],"date-time":"2016-08-15T13:01:05Z","timestamp":1471266065000},"page":"3844-3855","source":"Crossref","is-referenced-by-count":16,"title":["Aldosterone Synthase Inhibition Improves Glucose Tolerance in Zucker Diabetic Fatty (ZDF) Rats"],"prefix":"10.1210","volume":"157","author":[{"given":"Anja","family":"Hofmann","sequence":"first","affiliation":[{"name":"Division of Vascular Endothelium and Microcirculation (A.H., C.B., J.M., F.E., H.M., Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coy","family":"Brunssen","sequence":"additional","affiliation":[{"name":"Division of Vascular Endothelium and Microcirculation (A.H., C.B., J.M., F.E., H.M., Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Peitzsch","sequence":"additional","affiliation":[{"name":"Division of Clinical Neurochemistry (M.P., G.E.), Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Martin","sequence":"additional","affiliation":[{"name":"University Hospital Carl Gustav Carus Dresden, and Institute of Physiology (M.M., A.D.), Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Mittag","sequence":"additional","affiliation":[{"name":"Division of Vascular Endothelium and Microcirculation (A.H., C.B., J.M., F.E., H.M., Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anett","family":"Jannasch","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery (A.J.), Herzzentrum Dresden, Medical Faculty, Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Engelmann","sequence":"additional","affiliation":[{"name":"Division of Vascular Endothelium and Microcirculation (A.H., C.B., J.M., F.E., H.M., Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas F.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Cardio Metabolic Diseases (N.F.B., S.M.W.), Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut 06877"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Weldon","sequence":"additional","affiliation":[{"name":"Department of Cardio Metabolic Diseases (N.F.B., S.M.W.), Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut 06877"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Huber","sequence":"additional","affiliation":[{"name":"Department of Cardio Metabolic Diseases (J.H., R.S.), Boehringer Ingelheim Pharma GmbH and Co KG, 88400 Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Streicher","sequence":"additional","affiliation":[{"name":"Department of Cardio Metabolic Diseases (J.H., R.S.), Boehringer Ingelheim Pharma GmbH and Co KG, 88400 Biberach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Deussen","sequence":"additional","affiliation":[{"name":"University Hospital Carl Gustav Carus Dresden, and Institute of Physiology (M.M., A.D.), Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Eisenhofer","sequence":"additional","affiliation":[{"name":"Division of Clinical Neurochemistry (M.P., G.E.), Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"},{"name":"Institute of Clinical Chemistry and Laboratory Medicine, Department of Medicine III (G.E., S.R.B.), Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan R.","family":"Bornstein","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry and Laboratory Medicine, Department of Medicine III (G.E., S.R.B.), Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"},{"name":"Department of Endocrinology and Diabetes (S.R.B.), Division of Diabetes and Nutritional Sciences, Rayne Institute, Faculty of Life Sciences and Medicine, Kings College London, London, SE5 9PJ, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Morawietz","sequence":"additional","affiliation":[{"name":"Division of Vascular Endothelium and Microcirculation (A.H., C.B., J.M., F.E., H.M., Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2016,8,15]]},"reference":[{"key":"2019041121292248900_B1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJM198104163041602","article-title":"The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients","volume":"304","author":"Tuck","year":"1981","journal-title":"N Engl J Med"},{"key":"2019041121292248900_B2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0952-3278(99)80020-9","article-title":"Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans","volume":"60","author":"Goodfriend","year":"1999","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2019041121292248900_B3","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/01.HYP.0000154361.47683.d3","article-title":"Weight loss and the renin-angiotensin-aldosterone system","volume":"45","author":"Engeli","year":"2005","journal-title":"Hypertension"},{"key":"2019041121292248900_B4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-2008-1073128","article-title":"Increased aldosterone levels in a model of type 2 diabetes mellitus","volume":"117","author":"Fredersdorf","year":"2009","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2019041121292248900_B5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1749-6632.2002.tb04415.x","article-title":"The pathophysiology of aldosterone in the cardiovascular system","volume":"970","author":"Rocha","year":"2002","journal-title":"Ann NY Acad Sci"},{"key":"2019041121292248900_B6","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1007\/s00125-011-2158-9","article-title":"Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets","volume":"54","author":"Luther","year":"2011","journal-title":"Diabetologia"},{"key":"2019041121292248900_B7","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","article-title":"Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines","volume":"117","author":"Guo","year":"2008","journal-title":"Circulation"},{"key":"2019041121292248900_B8","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.tips.2011.07.006","article-title":"The renin-angiotensin-aldosterone system and glucose homeostasis","volume":"32","author":"Luther","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"2019041121292248900_B9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11906-015-0567-8","article-title":"Aldosterone and the mineralocorticoid receptor: risk factors for cardiometabolic disorders","volume":"17","author":"Garg","year":"2015","journal-title":"Curr Hypertens Rep"},{"key":"2019041121292248900_B10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.33549\/physiolres.930000.49.241","article-title":"Impaired insulin action in primary hyperaldosteronism","volume":"49","author":"Widimsky","year":"2000","journal-title":"Physiol Res"},{"key":"2019041121292248900_B11","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1097\/HJH.0b013e3282861fa4","article-title":"A possible association between primary aldosteronism and a lower \u03b2-cell function","volume":"25","author":"Mosso","year":"2007","journal-title":"J Hypertens"},{"key":"2019041121292248900_B12","first-page":"21","article-title":"Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment","volume":"108","author":"Sindelka","year":"2000","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2019041121292248900_B13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cvr\/cvp191","article-title":"Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice","volume":"84","author":"Hirata","year":"2009","journal-title":"Cardiovasc Res"},{"key":"2019041121292248900_B14","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1210\/en.2006-0826","article-title":"Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects","volume":"147","author":"Funder","year":"2006","journal-title":"Endocrinology"},{"key":"2019041121292248900_B15","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/HYPERTENSIONAHA.114.04912","article-title":"Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction","volume":"65","author":"Bender","year":"2015","journal-title":"Hypertension"},{"key":"2019041121292248900_B16","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.amjcard.2014.05.064","article-title":"Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial)","volume":"114","author":"Vaduganathan","year":"2014","journal-title":"Am J Cardiol"},{"key":"2019041121292248900_B17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1043-2760(02)00602-1","article-title":"Recent insights into organogenesis of the adrenal cortex","volume":"13","author":"Keegan","year":"2002","journal-title":"Trends Endocrinol Metab"},{"key":"2019041121292248900_B18","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00125-012-2814-8","article-title":"Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice","volume":"56","author":"Luo","year":"2013","journal-title":"Diabetologia"},{"key":"2019041121292248900_B19","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/eurheartj\/ehn277","article-title":"Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone","volume":"29","author":"Mulder","year":"2008","journal-title":"Eur Heart J"},{"key":"2019041121292248900_B20","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/ki.2009.9","article-title":"Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt","volume":"75","author":"Lea","year":"2009","journal-title":"Kidney Int"},{"key":"2019041121292248900_B21","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","article-title":"Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage","volume":"111","author":"Fiebeler","year":"2005","journal-title":"Circulation"},{"key":"2019041121292248900_B22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/ndt\/gfs388","article-title":"Aldosterone synthase inhibition in humans","volume":"28","author":"Azizi","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2019041121292248900_B23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0002-9440(10)63626-7","article-title":"Analysis of the Zucker diabetic fatty (ZDF) type 2 diabetic rat model suggests a neurotrophic role for insulin\/IGF-I in diabetic autonomic neuropathy","volume":"163","author":"Schmidt","year":"2003","journal-title":"Am J Pathol"},{"key":"2019041121292248900_B24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ilar.32.3.16","article-title":"Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus","volume":"32","author":"Peterson","year":"1990","journal-title":"ILAR J"},{"key":"2019041121292248900_B25","first-page":"531","article-title":"Variability in Zucker diabetic fatty rats: differences in disease progression in hyperglycemic and normoglycemic animals","volume":"7","author":"Wang","year":"2014","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2019041121292248900_B26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1475-2840-10-94","article-title":"Eplerenone prevents salt-induced vascular stiffness in Zucker diabetic fatty rats: a preliminary report","volume":"10","author":"Resch","year":"2011","journal-title":"Cardiovasc Diabetol"},{"key":"2019041121292248900_B27","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/01.HYP.0000203148.42892.7a","article-title":"Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts","volume":"47","author":"Kobayashi","year":"2006","journal-title":"Hypertension"},{"key":"2019041121292248900_B28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.foodhyd.2013.10.007","article-title":"Physicochemical properties and regulatory effects on db\/db diabetic mice of b-glucans extracted from oat, wheat and barley","volume":"37","author":"Zhao","year":"2014","journal-title":"Food Hydrocolloid"},{"key":"2019041121292248900_B29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jsbmb.2014.10.006","article-title":"An LC-MS\/MS method for steroid profiling during adrenal venous sampling for investigation of primary aldosteronism","volume":"145","author":"Peitzsch","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2019041121292248900_B30","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1097\/HJH.0b013e32833c2197","article-title":"FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice","volume":"28","author":"Gamliel-Lazarovich","year":"2010","journal-title":"J Hypertens"},{"key":"2019041121292248900_B31","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/01.hjh.0000226205.65442.f2","article-title":"Investigation of aldosterone-synthase inhibition in rats","volume":"24","author":"Menard","year":"2006","journal-title":"J Hypertens"},{"key":"2019041121292248900_B32","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1124\/jpet.110.167148","article-title":"Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11\u03b2-hydroxylase inhibitor metyrapone","volume":"334","author":"Rigel","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"2019041121292248900_B33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.mce.2003.10.010","article-title":"Glomerulosa function and aldosterone synthesis in the rat","volume":"217","author":"Vinson","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"2019041121292248900_B34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10741-005-2343-3","article-title":"Aldosterone biosynthesis, regulation, and classical mechanism of action","volume":"10","author":"Williams","year":"2005","journal-title":"Heart Fail Rev"},{"key":"2019041121292248900_B35","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1210\/jcem.84.5.5631","article-title":"Clinical review 104: adrenocorticotropin (ACTH)- and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs","volume":"84","author":"Bornstein","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121292248900_B36","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1113\/expphysiol.2008.042085","article-title":"Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats","volume":"93","author":"Siragy","year":"2008","journal-title":"Exp Physiol"},{"key":"2019041121292248900_B37","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/1475-2840-12-172","article-title":"Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type II diabetes","volume":"12","author":"Ramirez","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"2019041121292248900_B38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.steroids.2014.08.016","article-title":"Effects of aldosterone on insulin sensitivity and secretion","volume":"91","author":"Luther","year":"2014","journal-title":"Steroids"},{"key":"2019041121292248900_B39","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1161\/HYPERTENSIONAHA.110.165076","article-title":"GPR30, mineralocorticoid receptors, and the rapid vascular effects of aldosterone","volume":"57","author":"Funder","year":"2011","journal-title":"Hypertension"},{"key":"2019041121292248900_B40","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/HYPERTENSIONAHA.110.161653","article-title":"GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone","volume":"57","author":"Gros","year":"2011","journal-title":"Hypertension"},{"key":"2019041121292248900_B41","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1210\/jc.2012-3934","article-title":"Aldosterone excess impairs first phase insulin secretion in primary aldosteronism","volume":"98","author":"Fischer","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041121292248900_B42","first-page":"3","article-title":"Gastric electrical stimulation treatment of type 2 diabetes: effects of implantation versus meal-mediated stimulation. A randomized blinded cross-over trial","author":"Lebovitz","year":"2015","journal-title":"Physiol Rep"},{"key":"2019041121292248900_B43","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1124\/jpet.114.213454","article-title":"The sodium glucose cotransporter type 2 inhibitor empagliflozin preserves \u03b2-cell mass and restores glucose homeostasis in the male Zucker diabetic fatty rat","volume":"350","author":"Hansen","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"2019041121292248900_B44","doi-asserted-by":"crossref","first-page":"E110","DOI":"10.1152\/ajpendo.00258.2007","article-title":"Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat","volume":"295","author":"Lastra","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2019041121292248900_B45","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI119743","article-title":"Pancreatic \u03b2 cells are important targets for the diabetogenic effects of glucocorticoids","volume":"100","author":"Delaunay","year":"1997","journal-title":"J Clin Invest"},{"key":"2019041121292248900_B46","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1152\/physrev.00011.2014","article-title":"Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited","volume":"95","author":"Rossier","year":"2015","journal-title":"Physiol Rev"},{"key":"2019041121292248900_B47","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/jama.2015.9536","article-title":"Diabetes: advances in diagnosis and treatment","volume":"314","author":"Nathan","year":"2015","journal-title":"JAMA"},{"key":"2019041121292248900_B48","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev.me.36.020185.002241","article-title":"The molecular mechanism of insulin action","volume":"36","author":"Kahn","year":"1985","journal-title":"Annu Rev Med"},{"key":"2019041121292248900_B49","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1681\/ASN.2013111156","article-title":"Mechanisms of renal control of potassium homeostasis in complete aldosterone deficiency","volume":"26","author":"Todkar","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2019041121292248900_B50","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1210\/en.2004-1102","article-title":"Homeostatic responses in the adrenal cortex to the absence of aldosterone in mice","volume":"146","author":"Lee","year":"2005","journal-title":"Endocrinology"},{"key":"2019041121292248900_B51","doi-asserted-by":"crossref","first-page":"F61","DOI":"10.1152\/ajprenal.00257.2005","article-title":"Kidney function in mice lacking aldosterone","volume":"290","author":"Makhanova","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"2019041121292248900_B52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"key":"2019041121292248900_B53","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1097\/01.ASN.0000135971.88164.2C","article-title":"Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen","volume":"15","author":"Chander","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2019041121292248900_B54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00252649","article-title":"The effect of insulin on renal sodium metabolism. A review with clinical implications","volume":"21","author":"DeFronzo","year":"1981","journal-title":"Diabetologia"},{"key":"2019041121292248900_B55","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet"},{"key":"2019041121292248900_B56","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1210\/en.2009-0869","article-title":"Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet","volume":"151","author":"Wada","year":"2010","journal-title":"Endocrinology"},{"key":"2019041121292248900_B57","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.2337\/diacare.25.9.1511","article-title":"Diabetes contributes to cholesterol metabolism regardless of obesity","volume":"25","author":"Simonen","year":"2002","journal-title":"Diabetes Care"},{"key":"2019041121292248900_B58","first-page":"181","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"371","author":"Morawietz","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/157\/10\/3844\/10840920\/endo3844.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:14:55Z","timestamp":1749046495000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/157\/10\/3844\/2758354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,15]]},"references-count":58,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,8,15]]},"published-print":{"date-parts":[[2016,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2016-1358","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726639614.793525918","asserted-by":"object"}]},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,15]]}}}